Antiviral Therapy in Patients With Hematologic Malignancies, Transplantation, and Aplastic Anemia

Keyphrases

• Transplantation 100%
• Antiretroviral Therapy 100%
• Antiviral Agents 100%
• Hematological Malignancies 100%
• Aplastic Anemia 100%
• AIDS/HIV 50%
• Herpes Simplex Virus 50%
• Viral Hepatitis 50%
• Influenza 50%
• Infections In Immunocompromised Hosts 50%
• Virus Hepatitis 50%
• Cytomegalovirus 50%
• Varicella Zoster Virus 50%
• Hematopoietic Stem Cell Transplantation 25%
• Clinical Application 25%
• Antimicrobial 25%
• Opportunistic Infections 25%
• Adenovirus 25%
• Viral Infection 25%
• Host Defense 25%
• Supportive Care 25%
• Opportunistic Viral Infection 25%
• Community-acquired Respiratory Viruses 25%
• Herpesvirus 25%
• Compromised Host 25%

Medicine and Dentistry

• Antivirus Agent 100%
• Hematologic Malignancy 100%
• Antiviral Therapy 100%
• Hepatitis Virus 100%
• Aplastic Anemia 100%
• Human Immunodeficiency Virus 50%
• Virus Infection 50%
• Cytomegalovirus 50%
• Immunocompromised Patient 50%
• Herpes Simplex Virus 50%
• Varicella Zoster Virus 50%
• Hematopoietic Stem Cell Transplantation 25%
• Opportunistic Infection 25%
• Host Resistance 25%
• Adenoviridae 25%
• Supportive Care 25%
• Influenza Virus 25%
• Infection in Immunocompromised Patients 25%
• Herpesviridae 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Antivirus Agent 100%
• Hematologic Malignancy 100%
• Virus Hepatitis 100%
• Antiviral Therapy 100%
• Aplastic Anemia 100%
• Immunocompromised Patient 75%
• HIV 50%
• Cytomegalovirus 50%
• Herpes Simplex Virus 50%
• Virus Infection 50%
• Varicella Zoster Virus 50%
• Opportunistic Infection 25%
• Adenoviridae 25%
• Respiratory Virus 25%
• Herpesviridae 25%